References
- National Service Framework for Older People. March 2001. London: Department of Health.
- Diener HC, Cunha L, Forbes C et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. Journal of Neurological Science 1996; 143: 1–13.
- European Stroke Prevention Study 2. Efficacy and safety data. Journal of Neurological Science. 1997; 151 (Suppl): S1–77.
- Department of Health. Saving Lives: Our Healthier Nation. July 1999. London: HMSO.
- Chambers M, Hutton J, Gladman J. Cost- effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole. Pharmacoeconomics 1999; 16: 577–593.
- The Stroke Association. Stroke Fact Sheet. http://www.stroke.org.uk/noticeboard/ [facts.htm] accessed December 2003.
- Youman P, Wilson K, Harraf F, Kalra L. The economic burden of stroke in the United Kingdom. Pharmacoeconomics 2003; 21 (Suppl 1): 43–50.
- Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. British Medical Journal 2002; 324: 71–86.
- CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–1339.
- Van Swieten JC, Koudstall PJ, Visser MC et al. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988; 19: 604–607.
- Rankin J. Cerebral vascular accidents in patients over the age of 60. 2. Prognosis. Scottish Medical Journal 1957; 2: 200–215.
- Bamford J, Sandercock P, Dennis M et al. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981–86. 1. Methodology, demography and incident cases of first ever stroke. Journal of Neurology, Neurosurgery and Psychiatry 1988; 51: 1373–1380.
- Burn J, Dennis M, Bamford J et al. Long- term risk of recurrent stroke after a first- ever stroke. The Oxfordshire Community Stroke Project. Stroke 1994; 25: 333–337.
- NHS Reference Costs 2001. Department of Health: Leeds, 2001.
- Personal Social Services Research Unit (PSSRU). 2002. Unit Costs of Health and Social Care. Canterbury: PSSRU.
- British National Formulary: version 44; 2002.
- Tengs TO, Yu M, Luistro E. Health-related quality of life after stroke a comprehensive review. Stroke 2001; 32: 964–972.
- Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. Journal of the American Medical Association 1995; 274: 1839–1845.
- Post PN, Stiggelbout AM, Wakker PP. The utility of health states after stroke: a systematic review of the literature. Stroke 2001; 32: 1425–1429.
- NICE. Guidance for Manufacturers and Sponsors. Technology Appraisals Process Series No 5. June 2001. London: National Institute for Clinical Excellence.
- Chambers MG, Koch P, Hutton J. Development of a decision-analytic model of stroke care in the United States and Europe. Value in Health 2002; 5: 82–97.
- Hedman J, Kaprio J, Poss T, Nieminen M M. Prevalance of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. International Journal of Epidemiology 1999; 28: 717–722.
- Beech R, Rudd AG, Tilling K, Wolfe CD. Economic consequences of early inpatient discharge to community-based rehabilitation for stroke in an inner-London teaching hospital. Stroke 1999; 30: 729–735.